Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paraskevi C. Fragkou has a total of 304 co-authors. Here are the top co-authors by number of shared publications:

  • Sotirios Tsiodras

    4th Department of Internal Medicine, Medical School, University General Hospital Attikon, National and Kapodistrian University of Athens, 12462 Athens, Greece

    17 shared publications
  • Charalampos D. Moschopoulos

    Fourth Department of Internal Medicine, School of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece

    11 shared publications
  • Sotirios Tsiodras

    Fourth Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece

    7 shared publications
  • Chrysanthi Skevaki

    Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps-University Marburg, University of Giessen Marburg Lung Center (UGMLC), German Center for Lung Research (DZL), Marburg, Germany

    5 shared publications
  • Dimitra Dimopoulou

    Second Department of Pediatrics, “P. & A. Kyriakou” Children’s Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

    5 shared publications
  • Dimitra Dimopoulou

    Second Department of Pediatrics, Children’s General Hospital “Aglaia & Panagiotis Kyriakou”, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece

    5 shared publications

Latest Publications

  • Open Access

    Editorial: Emerging concepts for respiratory viruses after the pandemic

    by Dimitra Dimopoulou, Chrysanthi Skevaki, Fusun Can, Florence Morfin-Sherpa, Paraskevi C. Fragkou

    Respiratory virus research has been reshaped by the COVID-19 pandemic and the effects of climate change, both of which contributed to a shift in the epidemiology of respiratory viruses and highlighted gaps in our understanding about the plasticity and long-term consequences of these changes [1,2]. The pandemic also accelerated advances in research models and methods, underscoring evolving seasonality patterns, viral pathogenesis, and host interactions [1,2]. This research topic explored the changing epidemiology and pathogenesis of respiratory viruses, focusing on seasonality, long-term outcomes, and host responses. It also emphasized advances in diagnostics and therapeutics and the use of artificial intelligence for predictive modeling, aiming to inform public health strategies in the post-pandemic era.The COVID-19 pandemic has significantly impacted the epidemiology of respiratory viruses due to widespread public health interventions such as lockdowns, masking, social distancing and school closures that resulted in the interruption of the SARS-CoV-2 transmission and the seasonal dynamics of other respiratory viruses [3,4] To conclude, these studies demonstrate that the pandemic reshaped the epidemiology, seasonality, and clinical impact of respiratory viruses, and they highlight the ongoing vulnerabilities across pediatric and healthcare populations, as well as the need for continuous enhanced surveillance, vaccination, and targeted protective strategies to address future respiratory viral infection threats in the post-pandemic era.While a huge body of data on COVID-19 pathogenesis is currently available, many aspects of the complex host-pathogen interplay remain still unknown. Bugatti et al.showed that SARS-CoV-2 can infect ACE2-negative primary human lung microvascular endothelial cells (HL-mECs) through an alternative entry mechanism that relies on the Arg-Gly-Asp (RGD) motif expressed in the receptor binding domain Taken together, the studies featured in this collection offer a broad, yet detailed picture of how the pandemic has reshaped our understanding of respiratory viruses-from shifting in their circulation patterns to the emergence of new clinical and immunological insights. As we move forward, these observations emphasize the importance of flexible surveillance systems, thoughtful public health planning, and continued scientific investment to anticipate and respond to future challenges.

  • Open Access

    Prospective Neuropsychological and Plasma Biomarker Changes in Treatment-Naïve People Living with HIV After Antiretroviral Treatment Initiation

    by Charalampos D. Moschopoulos, Evangelia Stanitsa, Konstantinos Protopapas, Akrivi Vatsi, Irene Galani, Henrik Zetterberg, Ion Beratis, Paraskevi C. Fragkou, Sotirios Tsiodras, Dimitra Kavatha, et al.

    Introduction: Human immunodeficiency virus (HIV)-associated neurocognitive impairment (NCI) remains a concern despite combination antiretroviral therapy (cART), with cognitive problems often persisting even after viral suppression. The mechanisms underlying neurocognitive deterioration in people living with HIV (PLWH) and the role of plasma biomarkers remain unclear. This study aims to evaluate neurocognitive trajectories and biomarker changes in a real-world cohort of newly diagnosed PLWH initiating cART in Greece. Methods: This prospective, single-center study assessed neuropsychological performance and plasma biomarkers in treatment-naïve PLWH at baseline and 18 months after cART initiation. HIV-associated neurocognitive disorder (HAND) was classified using the Frascati criteria, and plasma biomarkers of inflammation and monocyte activation were measured. Correlations between biomarkers and cognitive performance were analyzed. Results: A total of 39 treatment-naïve PLWH were enrolled in this study. At baseline, 45.7% of participants met criteria for HAND, predominantly, asymptomatic neurocognitive impairment (ANI). Over 18 months, neurocognitive function improved, particularly in speed of information processing, executive function, and visuospatial ability, while verbal fluency, fine motor dexterity, and attention/working memory remained unchanged. Biomarkers of inflammation and monocyte activation decreased following cART, except for neopterin, which increased (10.6 vs. 13 ng/mL, p = 0.002), and plasma NFL (7.5 vs. 7.2 pg/mL, p = 0.54), which remained stable. A negative correlation between monocyte activation markers and cognitive performance was observed only at follow-up, suggesting that systemic inflammation may mask these associations in untreated PLWH. Conclusions: Early cART initiation supports neurocognitive recovery and reduces immune activation in PLWH. The observed correlation between cognitive performance and monocyte activation markers after viral suppression highlights the potential utility of plasma biomarkers in predicting cognitive impairment.


  • Open Access

    Editorial for Special Issue “Antimicrobial Treatment of Lower Respiratory Tract Infections”

    by Charalampos D. Moschopoulos, Anastasia Kotanidou, Sotirios Tsiodras, Paraskevi C. Fragkou

    Lower respiratory tract infections (LRTIs) are highly prevalent, and severe LRTIs are associated with significant mortality and morbidity worldwide


  • Open Access

    Duration of Antimicrobial Treatment in Adult Patients with Pneumonia: A Narrative Review

    by Dimitra Dimopoulou, Charalampos D. Moschopoulos, Konstantina Dimopoulou, Anastasia Dimopoulou, Maria M. Berikopoulou, Ilias Andrianakis, Sotirios Tsiodras, Anastasia Kotanidou, Paraskevi C. Fragkou

    Pneumonia remains a major global health concern, causing significant morbidity and mortality among adults. This narrative review assesses the optimal duration of antimicrobial treatment in adults with community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP). Current evidence about the impact of treatment duration on clinical outcomes demonstrates that shorter antibiotic courses are non-inferior, regarding safety and efficacy, compared to longer courses, particularly in patients with mild to moderate CAP, which is in line with the recommendations of international guidelines. Data are limited regarding the optimal antimicrobial duration in HAP patients, and it should be individually tailored to each patient, taking into account the causative pathogen and the clinical response. Shorter courses are found to be as effective as longer courses in the management of VAP, except for pneumonia caused by non-fermenting Gram-negative bacteria; however, duration should be balanced between the possibility of higher recurrence rates and the documented benefits with shorter courses. Additionally, the validation of reliable biomarkers or clinical predictors that identify patients who would benefit from shorter therapy is crucial. Insights from this review may lead to future research on personalized antimicrobial therapies in pneumonia, in order to improve patient outcomes.


  • Open Access

    Intensive Care Unit Mortality Trends during the First Two Years of the COVID-19 Pandemic in Greece: A Multi-Center Retrospective Study

    by Paraskevi C. Fragkou, Sotirios P. Karagiannis, Dimitra Dimopoulou, Sotiria Kefala, Fotini Fligou, Parisis Gallos, Edison Jahaj, Angeliki Bellou, Evangelia Koukaki, Eleni Magira, et al.

    Data on COVID-19 mortality among patients in intensive care units (ICUs) from Eastern and/or Southern European countries, including Greece, are limited. The purpose of this study was to evaluate the ICU mortality trends among critically ill COVID-19 patients during the first two years of the pandemic in Greece and to further investigate if certain patients’ clinical characteristics contributed to this outcome. We conducted a multi-center retrospective observational study among five large university hospitals in Greece, between February 2020 and January 2022. All adult critically ill patients with confirmed COVID-19 disease who required ICU admission for at least 24 h were eligible. In total, 1462 patients (66.35% males) were included in this study. The mean age of this cohort was 64.9 (±13.27) years old. The 28-day mortality rate was 35.99% (n = 528), while the overall in-hospital mortality was 50.96% (n = 745). Cox regression analysis demonstrated that older age (≥65 years old), a body mass index within the normal range, and a delay in ICU admission from symptom onset, as well as worse baseline clinical severity scores upon ICU admission, were associated with a greater risk of death. Mortality of critically ill COVID-19 patients was high during the first two years of the pandemic in Greece but comparable to other countries. Risk factors for death presented in this study are not different from those that have already been described for COVID-19 in other studies.


  • Open Access

    The Role of Automated Infrared Pupillometry in Traumatic Brain Injury: A Narrative Review

    by Charikleia S. Vrettou, Paraskevi C. Fragkou, Ioannis Mallios, Chrysanthi Barba, Charalambos Giannopoulos, Evdokia Gavrielatou, Ioanna Dimopoulou

    Pupillometry, an integral component of neurological examination, serves to evaluate both pupil size and reactivity. The conventional manual assessment exhibits inherent limitations, thereby necessitating the development of portable automated infrared pupillometers (PAIPs). Leveraging infrared technology, these devices provide an objective assessment, proving valuable in the context of brain injury for the detection of neuro-worsening and the facilitation of patient monitoring. In cases of mild brain trauma particularly, traditional methods face constraints. Conversely, in severe brain trauma scenarios, PAIPs contribute to neuro-prognostication and non-invasive neuromonitoring. Parameters derived from PAIPs exhibit correlations with changes in intracranial pressure. It is important to acknowledge, however, that PAIPs cannot replace invasive intracranial pressure monitoring while their widespread adoption awaits robust support from clinical studies. Ongoing research endeavors delve into the role of PAIPs in managing critical neuro-worsening in brain trauma patients, underscoring the non-invasive monitoring advantages while emphasizing the imperative for further clinical validation. Future advancements in this domain encompass sophisticated pupillary assessment tools and the integration of smartphone applications, emblematic of a continually evolving landscape.


  • Open Access

    Editorial: Immune response to respiratory viruses and respiratory viral infections in susceptible populations

    by Paraskevi C. Fragkou, Dimitra Dimopoulou, Giulia De Angelis, Giulia Menchinelli, Roy F. Chemaly, Chrysanthi Skevaki

    Editorial: Immune response to respiratory viruses and respiratory viral infections in susceptible populations

  • Open Access

    Endothelial Glycocalyx Integrity in Treatment-Naïve People Living with HIV before and One Year after Antiretroviral Treatment Initiation

    by Paraskevi C. Fragkou, Ignatios Ikonomidis, Dimitrios Benas, Dimitra Kavatha, Charalampos D. Moschopoulos, Konstantinos Protopapas, Gavriella Kostelli, John Thymis, Dionysia Mpirmpa, Irene Galani, et al.

    Endothelial glycocalyx (EG) derangement has been associated with cardiovascular disease (CVD). Studies on EG integrity among people living with HIV (PLWH), are lacking. We conducted a prospective cohort study among treatment-naïve PLWH who received emtricitabine/tenofovir alafenamide, combined with either an integrase strand transfer inhibitor (INSTI, dolutegravir, raltegravir or elvitegravir/cobicistat), or a protease inhibitor (PI, darunavir/cobicistat). We assessed EG at baseline, 24 (±4) and 48 (±4) weeks, by measuring the perfused boundary region (PBR, inversely proportional to EG thickness), in sublingual microvessels. In total, 66 consecutive PLWH (60 (90.9%) males) with a median age (interquartile range, IQR) of 37 (12) years, were enrolled. In total, 40(60.6%) received INSTI-based regimens. The mean (standard deviation) PBR decreased significantly from 2.17 (0.29) μm at baseline to 2.04 (0.26) μm (p = 0.019), and then to 1.93 (0.3) μm (p < 0.0001) at 24 (±4) and 48 (±4) weeks, respectively. PBR did not differ among treatment groups. PLWH on INSTIs had a significant PBR reduction at 48 (±4) weeks. Smokers and PLWH with low levels of viremia experienced the greatest PBR reduction. This study is the first to report the benefit of antiretroviral treatment on EG improvement in treatment-naïve PLWH and depicts a potential bedside biomarker and therapeutic target for CVD in PLWH.


  • Open Access

    New Insights into the Fluid Management in Patients with Septic Shock

    by Charalampos D. Moschopoulos, Dimitra Dimopoulou, Anastasia Dimopoulou, Konstantina Dimopoulou, Konstantinos Protopapas, Nikolaos Zavras, Sotirios Tsiodras, Anastasia Kotanidou, Paraskevi C. Fragkou

    The importance of fluid resuscitation therapy during the early stages of sepsis management is a well-established principle. Current Surviving Sepsis Campaign (SSC) guidelines recommend the early administration of intravenous crystalloid fluids for sepsis-related hypotension or hyperlactatemia due to tissue hypoperfusion, within the first 3 h of resuscitation and suggest using balanced solutions (BSs) instead of normal saline (NS) for the management of patients with sepsis or septic shock. Studies comparing BS versus NS administration in septic patients have demonstrated that BSs are associated with better outcomes including decreased mortality. After initial resuscitation, fluid administration has to be judicious in order to avoid fluid overload, which has been associated with increased mortality, prolonged mechanical ventilation, and worsening of acute kidney injury. The “one size fits all” approach may be “convenient” but it should be avoided. Personalized fluid management, based on patient-specific hemodynamic indices, provides the foundations for better patient outcomes in the future. Although there is a consensus on the need for adequate fluid therapy in sepsis, the type, the amount of administered fluids, and the ideal fluid resuscitation strategy remain elusive. Well-designed large randomized controlled trials are certainly needed to compare fluid choices specifically in the septic patient, as there is currently limited evidence of low quality. This review aims to summarize the physiologic principles and current scientific evidence regarding fluid management in patients with sepsis, as well as to provide a comprehensive overview of the latest data on the optimal fluid administration strategy in sepsis.


  • Open Access

    Autoantibodies are highly prevalent in non–SARS-CoV-2 respiratory infections and critical illness

    by Allan Feng, Emily Y. Yang, Andrew Reese Moore, Shaurya Dhingra, Sarah Esther Chang, Xihui Yin, Ruoxi Pi, Elisabeth K.M. Mack, Sara Völkel, Reinhard Geßner, et al.

    The widespread presence of autoantibodies in acute infection with SARS-CoV-2 is increasingly recognized, but the prevalence of autoantibodies in non–SARS-CoV-2 infections and critical illness has not yet been reported. We profiled IgG autoantibodies in 267 patients from 5 independent cohorts with non–SARS-CoV-2 viral, bacterial, and noninfectious critical illness. Serum samples were screened using Luminex arrays that included 58 cytokines and 55 autoantigens, many of which are associated with connective tissue diseases (CTDs). Samples positive for anti-cytokine antibodies were tested for receptor blocking activity using cell-based functional assays. Anti-cytokine antibodies were identified in > 50% of patients across all 5 acutely ill cohorts. In critically ill patients, anti-cytokine antibodies were far more common in infected versus uninfected patients. In cell-based functional assays, 11 of 39 samples positive for select anti-cytokine antibodies displayed receptor blocking activity against surface receptors for Type I IFN, GM-CSF, and IL-6. Autoantibodies against CTD-associated autoantigens were also commonly observed, including newly detected antibodies that emerged in longitudinal samples. These findings demonstrate that anti-cytokine and autoantibodies are common across different viral and nonviral infections and range in severity of illness.